Xconomy: Meissa Scores $30M to Test Vaccine for Dangerous Respiratory Virus

No vaccine is yet available for respiratory syncytial virus (RSV), which causes lung infections that, while usually mild, can be deadly for very young children. Biotech startup Meissa Vaccines, which aims to fill that treatment gap, announced today it raised $30 million to fund early-stage clinical trials for its experimental RSV vaccine.

Read the full article on Xconomy.